Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:06:13.650Z.
Calculation as of: 2026-10-06T15:06:13.650Z.
Quote observation: 2026-10-06T15:05:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.35B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.36B
EV/Sales Ratio
37.43x
TTM Avg
98.44x
3Y Avg
98.44x
5Y Avg
78.47x
Market Cap
$1.41B
EV/Sales Ratio
N/A
TTM Avg
781.47x
3Y Avg
902.36x
5Y Avg
638.00x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.35B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.36B | 37.43x | 98.44x | 98.44x | 78.47x |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.41B | N/A | 781.47x | 902.36x | 638.00x |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 6.64x | 6.81x | 12.09x | 18.83x |
| Kardigan, Inc. (KARD)vs › | $1.25B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 0.71x | 0.73x | 0.58x | 0.61x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
